Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharmaDive" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharmaDive for you to read. Along with our medical data and news we also list BioPharmaDive Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharmaDive Companies for you to search.
New study results could support approval of Darzalex in combination with three other drugs as a first-line treatment for certain patients with multiple myeloma.
A U.K. regulator accused the drugmaker of price gouging, citing a near-6,000% increase in the price of a generic thyroid drug over 10 years.
The latest settlement comes just two months after the drug distributor agreed to pay $260 million in connection with criminal charges for its subsidiary's pre-filled syringe program.
Combining Tivicay with J&J's Edurant, the new regimen offers patients a less burdensome treatment option than current combos of three or more drugs.
The launch of the AMR Centre at Alderley Park in the UK aims to fill the gap between basic research and the market for new antimicrobials.
The latest legal challenge pulls Optum into an ongoing battle that adds turmoil to a rapidly changing and consolidating space.
Shifting dynamics in the diabetes market are pushing the Danish drugmaker to pursue other therapeutic areas.
Under new Commissioner Gottlieb, the FDA has been looking to increase competition across markets by ushering more drugs through the system more efficiently.
The California biotech will now turn to an earlier clinical candidate, which it hopes could prove more effective in treating the neurodegenerative disease.
The move leaves Ardelyx's pipeline with a single Phase 3 candidate that has faced trouble in the clinic and skepticism among investors.
In an effort to put more resources behind clinical development of inclisiran, the drugmaker will take its headcount down to below 60 people.
The biotech is counting on biosimilars to help grow topline revenue, just as competition from the copycat biologics cuts into its biggest blockbusters.
The outlook for Vertex is bright, as positive data from experimental combination treatments could eventually position the biotech to reach 90% of cystic fibrosis patients.
With stateside sales of the anti-inflammation drug relatively flat, the big biotech lowered its 2020 guidance — and then saw its stock plummet.
After a disastrous advisory committee meeting and a refusal-to-file letter, the regulatory agency has handed down another rejection for the DMD drug.
Using the new corporate signature "Empowering Life," the French drugmaker seeks to unify its five business around a central message.
Through a deal with MacroGenics, Incyte is adding a second checkpoint inhibitor to its pipeline to test in combination with its slate of immunotherapies.
As research into the immune system booms, the two companies will investigate treatments that aim to use the body's defenses to fight neurodegenerative disorders.
Recent approvals of Trelegy Ellipta and Shingrix should help bolster the drugmaker's prospects in key areas as it prepares for a generic hit.
While the higher dose showed a clinical effect, GS-0976 didn't hit the mark at its lowest dose, and the study missed its additional endpoints.
New data integration tools can help make personalized medicine a reality — revolutionizing the treatment of cancer and other notoriously complex diseases.
When asked what company would be most interested in the gene therapy drugmaker, BioPharma Dive readers had mixed feelings, but Pfizer won out.
The FDA has now approved the blockbuster drug as a treatment for patients with generalized myasthenia gravis, an uncommon neruomuscular disorder.
The big biotech is paying $150 million to reclaim 15% of the Alzheimer's candidate's potential royalties, and may take the agreement one step further.
Analysts are focused on the possible divestiture of the eye care business, while Novartis' newer drugs help make up for competition to Gleevec.